RenovoRx RNXT
NASDAQ RNXT
$1.58 +0.03 (+1.94%)
At close: Oct 2, 2026 · 4:00 PM EDT

RenovoRx (RNXT) Return on Sales [ROS] (2025 - 2026)

Updated

RenovoRx (RNXT) recorded Return on Sales [ROS] of -368.43% in Q2 2026, up 266.17 percentage points from -634.60% a year earlier and up 247.74 percentage points from the prior quarter.

Analysis

RenovoRx (RNXT) Return on Sales [ROS] (2025 - 2026) Analysis & Trends

On a TTM basis, RenovoRx's Return on Sales [ROS] came in at -685.22% as of Jun 30, 2026; for FY2025, it came in at -1113.98%, up 24397.65 percentage points from FY2024.

  • Across earlier years, Return on Sales [ROS] came in at -25511.63% in FY2024.
  • Per Business Quant, the preceding three quarters came in at -616.16% (Q1 2026), -1479.83% (Q4 2025) and -1203.01% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Thermo Fisher Scientific 241.25 Bn 220.40 Bn 4.88 Bn 17.40%
2 Abbott Laboratories 167.33 Bn 138.41 Bn 7.27 Bn 13.44%
3 Danaher 148.83 Bn 132.65 Bn 3.61 Bn 17.99%
4 Intuitive Surgical 142.00 Bn 121.55 Bn 1.96 Bn 33.60%
5 Medtronic 110.70 Bn 76.57 Bn 6.34 Bn 18.08%
6 Stryker 104.72 Bn 90.84 Bn 4.50 Bn 25.18%
7 Boston Scientific 62.66 Bn 57.67 Bn 3.85 Bn 21.65%
8 Edwards Lifesciences 49.13 Bn 33.24 Bn 1.35 Bn 29.48%
9 Becton Dickinson 48.51 Bn 45.66 Bn 2.32 Bn 13.31%
10 RenovoRx 69.94 Mn 69.94 Mn 766,000.00 -368.43%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -368.43%
Mar 31, 2026 -616.16%
Dec 31, 2025 -1,479.83%
Sep 30, 2025 -1,203.01%
Jun 30, 2025 -634.60%
Mar 31, 2025 -1,578.68%
API Access

RenovoRx Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=RNXT&period=max&api_key=YOUR_API_KEY